1.19
+0.18(+17.82%)
Currency In USD
| Previous Close | 1.01 |
| Open | 1.03 |
| Day High | 1.35 |
| Day Low | 1.03 |
| 52-Week High | 19.51 |
| 52-Week Low | 0.51 |
| Volume | 1.1M |
| Average Volume | 315,431 |
| Market Cap | 39.39M |
| PE | -10.82 |
| EPS | -0.11 |
| Moving Average 50 Days | 0.81 |
| Moving Average 200 Days | 2.65 |
| Change | 0.18 |
If you invested $1000 in JUPITER NEUROSCIENCES, INC. (JUNS) since IPO date, it would be worth $0 as of July 02, 2025 at a share price of $1.278. Whereas If you bought $1000 worth of JUPITER NEUROSCIENCES, INC. (JUNS) shares 0 years ago, it would be worth $232.82 as of July 02, 2025 at a share price of $1.278.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery
GlobeNewswire Inc.
Jun 30, 2025 7:15 PM GMT
PWR delivers science-driven cellular energy and recovery support as part of Jupiter’s expanding longevity supplement portfolio Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company
Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science
GlobeNewswire Inc.
Jun 27, 2025 12:00 PM GMT
GLO targets the growing ”beauty-from-within” market with scientifically proven cellular defense and skin vitality benefits Jupiter, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"),
Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador
GlobeNewswire Inc.
Jun 23, 2025 12:00 PM GMT
Partnership supports near-term launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, June 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) today announced that